Cogent Biosciences, Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Cogent Biosciences, Inc. (COGT) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $1.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-10
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-06-30 was $0.00.
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2026-03-31 was $1.06M, a 81.85% increase year-over-year.
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $0.00.
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $766.00K, a 36.54% increase year-over-year.
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $1.35M, a 47.38% increase from fiscal 2024.
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $916.00K, a 21.81% increase from fiscal 2023.
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $752.00K, a 114.25% increase from fiscal 2022.
- Cogent Biosciences, Inc. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $351.00K, a 1032.26% increase from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.06M 10-Q · filed 2026-08-10 | $1.06M derived: sum of 3 quarters · filed 2026-08-10 | $1.83M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-05 | $1.06M derived: sum of 2 quarters · filed 2026-05-05 | $1.83M derived: sum of 3 quarters · filed 2026-05-05 | $1.83M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $766.00K derived: sum of 2 quarters · filed 2026-02-17 | $766.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.35M 10-K · filed 2026-02-17 |
| 2025-09-30 | $766.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $766.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.35M 10-Q · filed 2025-11-07 | $1.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $584.00K 10-Q · filed 2026-08-10 | $583.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.14M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $584.00K 10-Q · filed 2026-05-05 | $583.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.14M derived: sum of 3 quarters · filed 2026-05-05 | $1.14M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $560.00K derived: sum of 2 quarters · filed 2026-02-17 | $560.00K derived: sum of 3 quarters · filed 2026-02-17 | $916.00K 10-K · filed 2026-02-17 |
| 2024-09-30 | $561.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $561.00K derived: sum of 2 quarters · filed 2025-11-07 | $917.00K 10-Q · filed 2025-11-07 | $917.00K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $356.00K 10-Q · filed 2025-08-05 | $356.00K derived: sum of 3 quarters · filed 2026-02-17 | $795.00K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $356.00K 10-Q · filed 2025-05-06 | $356.00K derived: sum of 2 quarters · filed 2026-02-17 | $795.00K derived: sum of 3 quarters · filed 2026-02-17 | $795.00K derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $439.00K derived: sum of 2 quarters · filed 2026-02-17 | $439.00K derived: sum of 3 quarters · filed 2026-02-17 | $752.00K 10-K · filed 2026-02-17 |
| 2023-09-30 | $439.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $439.00K derived: sum of 2 quarters · filed 2024-11-12 | $752.00K 10-Q · filed 2024-11-12 | $752.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $313.00K 10-Q · filed 2024-08-06 | $313.00K derived: sum of 3 quarters · filed 2025-02-25 | $535.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $313.00K 10-Q · filed 2024-05-07 | $313.00K derived: sum of 2 quarters · filed 2025-02-25 | $535.00K derived: sum of 3 quarters · filed 2025-02-25 | $535.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $222.00K derived: sum of 2 quarters · filed 2025-02-25 | $222.00K derived: sum of 3 quarters · filed 2025-02-25 | $351.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $222.00K derived: sum of 2 quarters · filed 2023-11-07 | $351.00K 10-Q · filed 2023-11-07 | $351.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $129.00K 10-Q · filed 2023-08-08 | $129.00K derived: sum of 3 quarters · filed 2024-02-26 | |
| 2022-03-31 | $129.00K 10-Q · filed 2023-05-09 | $129.00K derived: sum of 2 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $31.00K 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $31.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $13.00K derived: sum of 2 quarters · filed 2022-03-15 | $13.00K derived: sum of 3 quarters · filed 2022-03-15 | $48.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $13.00K derived: sum of 2 quarters · filed 2021-11-10 | $48.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $35.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $35.00K 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |